PMID: 7820182Jan 1, 1994Paper

The clinical experience with interleukin-2 in cancer therapy

Cancer Biotherapy
R O Dillman

Abstract

In May 1992, interleukin-2 (IL-2) was formally approved by the U.S. Food and Drug Administration for use in cancer treatment based on its activity in metastatic renal cell carcinoma. IL-2 alone or in combination with activated lymphocytes or other cytokines has significant anti-tumor activity against renal cell carcinoma and melanoma with response rates of 15-20%, some of which are quite durable. Limited anti-tumor effects have been noted in some patients with colorectal cancer and lymphoma. Too few patients have been studied to establish the level of activity in most other specific tumor types. The mechanism of this anti-tumor effect appears to be entirely mediated by the immunostimulatory effects of IL-2. Toxicities are dose related, but are substantial and similar regardless of the schedule of administration. Randomized trials have failed to establish (1) the superiority of high-dose bolus over continuous infusion IL-2, (2) the superiority of IL-2 plus interferon over IL-2 alone, or (3) the superiority of IL-2 plus LAK cells versus IL-2 alone. Further investigation is needed to determine the optimum dose and schedule from the standpoint of cost:benefit and risk:benefit, and to determine the role of IL-2 in the therapy of oth...Continue Reading

References

Mar 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A FiglinJ deKernion
May 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P F GeertsenK Steven
Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D H IlsonG J Bosl
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P A PalmerC R Franks
Jan 15, 1992·Cancer·J M RichardsN J Vogelzang
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G R WeissM H Bar
Dec 1, 1991·Cancer·D J SchwartzentruberS A Rosenberg
Mar 15, 1991·Cancer·J M RichardsN J Vogelzang
Oct 15, 1990·Annals of Internal Medicine·L A Rubin, D L Nelson
Sep 1, 1990·The American Journal of Medicine·P A PaciucciJ F Holland
Jan 15, 1990·Annals of Internal Medicine·D R SnydmanM B Atkins
Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P DutcherD H Boldt
Oct 1, 1987·The Journal of Experimental Medicine·H M Wang, K A Smith
Dec 15, 1988·Annals of Internal Medicine·E R GaynorR I Fisher
Jun 1, 1987·Annals of Internal Medicine·A BelldegrunS A Rosenberg
Sep 1, 1987·Annals of Internal Medicine·K D DenicoffS A Rosenberg
Dec 18, 1987·Science·B J BrandhuberD B McKay
Jul 11, 1983·Nucleic Acids Research·R DevosW Fiers
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S D FossåL Theodorsen
Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N J VogelzangR A Figlin
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SparanoG R Weiss

❮ Previous
Next ❯

Citations

Apr 1, 1996·Cancer·J BrittendenO Eremin
Aug 30, 2003·Current Pain and Headache Reports·Jonathan R Kerr, David A J Tyrrell
Jan 25, 2005·Cancer Biotherapy & Radiopharmaceuticals·Maria Evangelista-DeanWalter Quan
Oct 27, 2005·Cancer Biotherapy & Radiopharmaceuticals·Paul R WalkerWalter D Y Quan
Jul 19, 2012·Cancer Biotherapy & Radiopharmaceuticals·Robert O DillmanStephanie E McClure
Jan 8, 2015·Immunological Investigations·Vahid BahrambeigiShaghayegh Haghjooy Javanmard
Nov 15, 2008·Journal of Pharmaceutical Sciences·Mohamed A Shaker, Husam M Younes
Oct 2, 2003·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·R PowellJ Almond
Jul 12, 2011·Journal of Surgical Oncology·Kirsty U BoydClaire L F Temple
Sep 11, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Mustapha AllamLyne Gagnon
Dec 24, 1997·Disease-a-month : DM·W D Quan, C S Palackdharry
Oct 26, 2001·Hematology/oncology Clinics of North America·L L WorthE S Kleinerman
Aug 29, 2007·Clinical Journal of Oncology Nursing·Charley Cowan Tyre, Walter Quan
Jun 10, 2017·Immunotherapy·Ziqi TaoSantosh Kesari
Jan 25, 2005·Cancer Biotherapy & Radiopharmaceuticals·Robert DillmanShankar Nayak
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·R O Dillman
Apr 2, 2002·Avian Diseases·Guangxing LiHyun S Lillehoj
Apr 22, 1999·The Journal of Laryngology and Otology·N K Green, I A McNeish
Apr 26, 2003·American Journal of Clinical Oncology·Robert O DillmanPeter Vanderplas
Aug 1, 1997·Cancer Biotherapy & Radiopharmaceuticals·R O DillmanM C Wiemann

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.